BioCentury | Dec 4, 2020
Product Development

AZ’s opportunity to expand the severe asthma market with tezepelumab

...the release of the epithelial cytokines TSLP, IL-33...
...Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Dupixent also targets IL-4R.TSLP, IL-33...
...– Interleukin-5IL-13 – Interleukin-13IL-25 (IL-17E) – Interleukin-25IL-33 (NF-HEV...
BioCentury | Nov 13, 2020
Product Development

A huge sigh of relief, but a long road ahead: AZ’s Pangalos on COVID-19 in a BioCentury audio interview

...of the proof of concept basket studies that's being run in the U.K. Our anti IL-33...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Inhibiting IL-33-driven inflammation to treat brain cancer

...of the disease, ectopic tumor expression of IL-33 accelerated tumor progression, while tumor expression of IL-33...
...Next steps include developing compounds that inhibit nuclear activity by IL-33.AnaptysBio Inc. (NASDAQ:ANAB) has the anti-IL-33...
...Phase II testing for atopic dermatitis and Phase I testing for autoimmune diseases.TARGET/MARKER/PATHWAY: Interleukin-33 (IL-33; NF-HEV)EXPERIMENTAL...
BioCentury | Apr 30, 2020
Product Development

U.K.’s ACCORD platform trial to feed therapies into COVID-19 master protocols

...inhibitor Calquence acalabrutinib, which AZ markets to treat chronic lymphocytic leukemia (CLL); and MEDI3506, an anti-IL-33...
...Targets AXL (UFO) - AXL receptor tyrosine kinase Btk - Bruton’s tyrosine kinase IL-33 (NF-HEV...
BioCentury | Jan 31, 2020
Distillery Therapeutics

TNFR2 and IL-33 identified as targets in Dupuytren's disease

...myofibroblasts secreting 60% of the total IL-33 in the nodules. AnaptysBio Inc. (NASDAQ:ANAB) has the anti-IL-33...
...targeting IL-33, in Phase II testing for atopic dermatitis. AstraZeneca plc (LSE:AZN; NYSE:AZN) has the anti-IL-33...
...Phase I testing for COPD. TARGET/MARKER/PATHWAY: Tumor necrosis factor receptor 2 (TNFR2; TNFRSF1B); interleukin-33 (IL-33; NF-HEV...
BioCentury | Jan 30, 2020
Distillery Therapeutics

IL1RL1 in Treg cells as a lung cancer target

...DISEASE CATEGORY: Cancer INDICATION: Lung cancer Inhibiting IL1RL1, which signals in response to IL-33 binding, in...
...GSK3772847 in Phase II for asthma. TARGET/MARKER/PATHWAY: Interleukin-1 receptor-like 1 (IL1RL1; ST2; IL-33R); Interleukin-33 (IL-33; NF-HEV...
...Institute of Technology, Cambridge, Mass. email: tjacks@mit.edu Claire Quang Broad Institute of MIT and Harvard Massachusetts Institute of Technology Interleukin-33 (IL-33) (NF-HEV) Interleukin-1...
BioCentury | Jan 10, 2020
Company News

Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

...pair of identical Phase III trials to treat atopic dermatitis. LY3375880 is a mAb against IL-33...
...targeting IL-33 for atopic dermatitis took a hit in November after AnaptysBio Inc. (NASDAQ:ANAB) said IL-33...
BioCentury | Nov 8, 2019
Clinical News

AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb

...AnaptysBio lost over $700 million in market cap Friday after reporting that IL-33 inhibitor etokimab, which...
...quarter. AnaptysBio shares had already taken a hit in June following a readout from another anti-IL-33...
...CD213A1) - Interleukin-13 receptor α 1; IL-4R (IL-4RA; CD124) - Interleukin-4 receptor; IL-33 (NF-HEV) - Interleukin-33...
BioCentury | Jul 10, 2019
Distillery Therapeutics

Prophylactic IL-33 could treat infections

...treatment with IL-33 could reduce the severity of C. difficile infection. Colon biopsy levels of IL-33...
...IL-33 pre-treatment reduced mortality, weight loss, clinical disease scores and epithelial barrier damage. TARGET/MARKER/PATHWAY: Interleukin-33 (IL-33...
...pre-treatment reduced mortality, weight loss, clinical disease scores and epithelial barrier damage. TARGET/MARKER/PATHWAY: Interleukin-33 (IL-33; NF-HEV...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...said they are anticipating a potential readout from AnaptysBio Inc.’s Phase IIb ATLAS trial of anti-IL-33...
...treat atopic dermatitis. Expectations of the data have fallen since June 21, however, when another anti-IL-33...
...peptide GnRH - gonadotropin-releasing hormone HIF-PH - Hypoxia-inducible factor prolyl hydroxylase (EGLN) IL-33 - Interleukin-33 (NF-HEV...
Items per page:
1 - 10 of 71